Company profile

Ticker
ADXS
Exchange
Website
CEO
Kenneth A. Berlin
Employees
Incorporated
Location
Fiscal year end
Former names
GREAT EXPECTATIONS & ASSOCIATES INC
SEC CIK
IRS number
841521955

ADXS stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Jun 20
11 Aug 20
31 Oct 20

News

Company financial data Financial data

Quarter (USD) Apr 20 Jan 20 Oct 19 Jul 19
Revenue 250K 3K 1K 6K
Net income -6.32M -7.86M -10.19M -9.86M
Diluted EPS -0.1 -0.15 -0.15 -1
Net profit margin -2529% -261900% -1018800% -164300%
Operating income -6.32M -7.89M -10.29M -10.13M
Net change in cash -5.94M 1.79M -9.39M 8.05M
Cash on hand 28.22M 34.16M 32.36M 41.76M
Annual (USD) Oct 19 Oct 18 Oct 17 Oct 16
Revenue 20.88M 6.06M 12.03M 3.99M
Net income -16.61M -66.52M -93.44M -73.56M
Diluted EPS -1.09 -19.36 -2.31 -2.08
Net profit margin -79.54% -1097% -777% -1841%
Operating income -17.97M -70.38M -98.45M -76.49M
Net change in cash -11.78M 20.24M -88.85M 46.19M
Cash on hand 32.36M 44.14M 23.9M 112.75M

Financial data from Advaxis earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
4 May 20 Henderson Molly Options Common Stock Grant Aquire A No 0.66 50,000 33K 50,000
4 May 20 Khleif Samir N Options Common Stock Grant Aquire A No 0.66 13,000 8.58K 13,000
4 May 20 Appel Roni Options Common Stock Grant Aquire A No 0.66 13,000 8.58K 13,000
4 May 20 Berlin Kenneth A Options Common Stock Grant Aquire A No 0.66 50,000 33K 50,000
4 May 20 Patton James P Option Common Stock Grant Aquire A No 0.66 13,000 8.58K 13,000
11.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 32 34 -5.9%
Opened positions 7 4 +75.0%
Closed positions 9 10 -10.0%
Increased positions 10 9 +11.1%
Reduced positions 3 6 -50.0%
13F shares
Current Prev Q Change
Total value 3.67M 5.49M -33.0%
Total shares 6.93M 6.39M +8.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Renaissance Technologies 3.61M $1.91M -4.5%
BLK BlackRock 847.1K $449K +38.3%
Vanguard 805.28K $427K +283.7%
Geode Capital Management 428.01K $226K -5.3%
N Price T Rowe Associates 400.45K $212K +131.1%
Susquehanna International 350.1K $186K +2470.9%
Private Advisor 200.8K $106K +99.2%
NTRS Northern Trust 64.87K $34K +120.8%
Raymond James Financial Services Advisors 50K $27K 0.0%
HighTower Advisors 40K $21K NEW
Largest transactions
Shares Bought/sold Change
Vanguard 805.28K +595.4K +283.7%
Boothbay Fund Management 0 -391.25K EXIT
DAFNA Capital Management 0 -350K EXIT
Susquehanna International 350.1K +336.48K +2470.9%
BLK BlackRock 847.1K +234.78K +38.3%
N Price T Rowe Associates 400.45K +227.2K +131.1%
Renaissance Technologies 3.61M -169.66K -4.5%
Adage Capital Partners GP, L.L.C. 0 -166.67K EXIT
Private Advisor 200.8K +100K +99.2%
HighTower Advisors 40K +40K NEW

Financial report summary

?
Management Discussion
  • Revenue decreased approximately $20.6 million to $0.3 million for the six months ended April 30, 2020 compared to $20.9 million for the six months ended April 30, 2019. The decrease was due to a change in the estimated performance period associated with upfront fees received from Amgen in conjunction with the collaboration agreement signed in August 2016. On December 10, 2018, we received a written notice of termination from Amgen with respect to the Amgen Agreement. The termination was effective as of February 8, 2019. As of the notification date, we adjusted revenue on a cumulative catch-up basis considering the revised measure of progress for the combined performance obligation based on the modified service period up to and through the contract termination date of February 8, 2019 resulting in total revenue of $18.7 million in the prior period. In addition, the reimbursement of research and development costs of approximately $2.0 million by Amgen was included in revenue in the prior period.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: aimed, ATM, attract, avoid, AXA, bear, brought, buyback, Certificate, combat, comment, consummated, consummation, contact, difficult, disruption, disruptive, drove, duration, economy, effectuate, efficiency, epidemic, evolving, explore, extent, hereof, highly, law, macroeconomic, manner, ourLmplatform, outbreak, pace, page, pandemic, ratified, raw, regimen, rely, remote, repudiated, school, stockholder, temporary, ultimate, unfit, unusually, workforce
Removed: achieved, aforementioned, disposition, enrolling, harbor, hold, lifted, likelihood, Litigation, offset, open, partially, Reform, respond, step, unfavorable, worked

Patents

APP
Utility
Compositions and Methods Comprising KLK3 or FOLH1 Antigen
5 Mar 20
The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
APP
Utility
Combination of Listeria-based Vaccine with ANTI-CTLA-4 or ANTI-CD137 Antibodies
27 Feb 20
The subject matter described herein is directed to methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain expressing a construct comprising at least one human papillomavirus antigen in combination with one or more other therapeutic agents to treat a tumor or metastatic cancer.
APP
Utility
Personalized Delivery Vector-based Immunotherapy and Uses Thereof
19 Dec 19
This invention provides a system of providing and creating personalized immunotherapeutic compositions for a subject having a disease or condition, including therapeutic immunotherapy delivery vectors and methods of making the same comprising gene expression constructs expressing peptides associated with one or more neo-epitopes or peptides containing mutations that are specific to a subject's cancer or unhealthy tissue.
APP
Utility
Immunogenic Compositions Targeting Recurrent Cancer Mutations And Methods Of Use Thereof
24 Oct 19
Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins.